Phaseline

Companies › Grifols Therapeutics

Grifols Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 4 Phase 3; Respiratory, Neurology, Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Alpha-1 15% (DRUG): Alpha1-Proteinase Inhibitor Subcutaneous (Human), 15%
Protease inhibitor replacement therapy - recombinant alpha-1 antitrypsin (AAT) replacement
SERPINA1Phase 3Alpha 1 Antitrypsin DeficiencySep 2027
Xembify
Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified
–Phase 3CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy); HypogammaglobulinemiaDec 2027
.Alpha.1-Proteinase Inhibitor Human
Leukocyte elastase inhibitor
ELANEPhase 3Pulmonary Emphysema in Alpha-1 PI Deficiency–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT01983241.Alpha.1-Proteinase Inhibitor HumanPhase 3Pulmonary Emphysema in Alpha-1 PI DeficiencyRespiratoryJul 2026
NCT07555483Alpha-1 15% (DRUG): Alpha1-Proteinase Inhibitor Subcutaneous (Human), 15%Phase 3Alpha 1 Antitrypsin DeficiencyRespiratorySep 2027
NCT07540221XembifyPhase 3CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)NeurologyDec 2027
NCT05645107XembifyPhase 3HypogammaglobulinemiaOncologyAug 2029

Targets

SERPINA1 (1) ELANE (1)

Companies with the same targets

Krystal Biotech Takeda Tessera Therapeutics Wave Life Sciences USA Beam Therapeutics Onchilles Pharma CSL Behring

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.